Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy

( NCT02834663 / CRFB002DKR03T )

Informed Consent Form

Edition Number : 1.0 Edition

Generation Date : Jan 18, 2017

Principal Investigator : Yun-sik Yang

Research Institute : NOVARTIS KOREA LTD. And WONWANG UNIVERSITY HOSPITAL
Informed Consent Form

This research officer will agree to participate in clinical research from you and follow relevant regulations when documenting it and will follow legal procedures based on ethical principles based on the Helsinki Declaration.

You should read this consent carefully before deciding whether or not to participate in this study. It is important that you understand why this study is being done and what it is doing. You can ask any question as you read this document describing this study. Please decide with sufficient time. Please ask as many questions as you need to decide whether or not to participate in this study.

When you have answered all of your questions and have decided that you would like to participate in this study, please sign this document to begin participating in this study. You and the person responsible for the study who described this document (or someone authorized by the person responsible for research) must sign this form and write the date in hand.

Your signature means that you have been told about this clinical study. In addition, your signature on this document means that you (or your legal representative) want to participate in this study.

It is important to read and understand this manual before agreeing to participate in this study. This manual describes the purpose, procedure, benefit, risk, discomfort and caution of this study. It also describes the subject's right to stop participating in the study at any time. It is very important that the study subject properly informs the doctor of all of his or her past medical history, so during this study the doctor should do his best to ensure that the study is conducted in the safest way possible.

Before signing the consent form, please take sufficient time to consider and read the manual, and if necessary, consult with your family or others.

Research Background

Diabetic retinopathy is a major disease that causes macular edema and angiogenesis, leading to acquired blindness after the 20s. The prevalence of type 2 diabetes is increasing in the younger generation, which means an increased risk of retinopathy impairing vision.
There is microvascular perfusion in early diabetic retinopathy and many recent studies have reported that it is associated with clinical macular edema of mild to moderate non-proliferative diabetic retinopathy. In addition, many studies report that the number and turnover rate of microvascular perfusion are important prognostic factors for estimating the progression and regression of diabetic retinopathy. This decrease, which indicates that the regression of diabetic retinopathy and its therapeutic effect.

Purpose of the research

To evaluate the effect of Ranibizumab injection on microvascular changes in eyes with mild to moderate non-proliferative diabetic retinopathy with macular edema

Research Participation

Participation in research is voluntary. If you refuse to participate in the study or decide to stop participating, you will not have any negative impact on your future medical care. We will also notify you of any changes in the progress of our research that may affect our willingness to participate.

The researcher or regulatory agency may terminate the study early. Upon early termination, the research physician will notify you immediately and explain the reason for the termination. In this case, your information recording and information collection will be stopped during the study, but normal standard treatment will continue.

Study Period, Procedure and Method

When first enrolled in the target patient group, after initial evaluation, a visit to the ophthalmologist is conducted every month to perform Ranibizumab injections and basic ophthalmology examinations (for a total of 6 months). Inject mg. Fluorescent fundus angiography and light coherence tomography are performed at the initial evaluation and at 3 months and 6 months, the last visit. Fluorescent fundus angiography and fundus photography are analyzed to evaluate microvascular changes (microvascular, non-perfused areas, hard exudates, cotton patches). In addition, we investigate whether the central macular thickness, adverse reactions, etc.
Research Risk

There is no risk associated with participating in the study beyond the risks of general testing and treatment. For fluorescein angiography, you are given a fluorescent dye injection into your vein (which glows green when exposed to certain types of light). Risks associated with fluorography (dye examination) may include bleeding and bruising at the injection site, nausea and sometimes vomiting. Mild reactions, such as itching, edema, or redness at or around the injection site, occur about 1 out of every 100 times. Allergic reactions to more severe fluorescent dyes (contrast agents) can also occur: this includes severe edema and dyspnea, which can occur in 1 in 10,000 people. Fluorescent dye injections can cause heart attack, stroke, or death in about 1 in 222,000 people. If you have had a severe allergic reaction to fluorescent dyes before, you cannot participate in this clinical study.

Research Benefits

Study subjects participated in this study and received a total of 6 intravitreal injections of ranibizumab once a month. Even if you don’t participate, you will receive general testing and treatment. The results of this study will contribute to making guidelines for diagnosis and treatment of patients similar to those of the future study.

Cost and compensation

Ranibizumab injections (0.5 mg) given at each visit are provided free of charge by Novartis. In addition, inspection fees (light coherence tomography, fluorescein angiography examination) and transportation expenses are provided for each visit.

Subject's Compliance

Initial evaluations and monthly visits to the hospital are required to conduct surveys and eye exams. You should also report any abnormal symptoms to your research doctor or research staff.
Privacy

If you participate in this study, this study collects your personal information (names are recorded as initials and managed by a study management number. Personal identification information and health information, etc.). The personal information collected in this way is strictly managed in accordance with relevant laws and regulations, and only the personnel involved in the research, health authorities, and sponsors’ inspectors can access the collected data. Personally identifiable information among collected personal information is not directly used or necessary for research, but is used only for the purpose of linking you with clinical data obtained through research. In addition, the personal identification list is kept and transferred to the IRB for up to three years after the study is conducted. Your personal information will be used until the research purpose is achieved, and the collected information will be properly managed in accordance with the Personal Information Protection Act.

Whether or not to participate in this study is entirely at your option and there will be no penalty for not participating. In addition, even after consenting to participate, if you wish to withdraw your consent, you can request that the investigated data be discarded. In this case, all materials except for the information and resources already used in the study will be disposed of in accordance with legitimate procedures.

The collected data is integrated with data obtained from other participants in the study, and the results can be used as a scientific basis, including referrals at the time of study, publication or meeting. Your identity will not be disclosed if a publication or report on the results of this study is published.

Inquiries

As a participant in this study, you may contact the Institutional Bioethics Committee (063 859 2232) if you have any questions about your rights, if you have any questions related to the study, or if you suspect any adverse reactions have occurred.

* If you have any questions about this study, or if there is any danger, inconvenience, or damage, please contact the above researchers.
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Dibetic retinopathy (NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: ___________________ Date of signature: _____________

Signature by legal agent (if necessary): ________ Date of signature: _____________

Witness signature (if necessary): ______________ Date of signature: _____________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: ___________________ Date of signature: _____________
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: ____________________________ Date of signature: 2016. 8. 11

Signature by legal agent (if necessary): _______________ Date of signature: ____________________

Witness signature (if necessary): _____________________ Date of signature: ____________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: _________________________ Date of signature: 2016. 8. 11
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Dibetic retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature:  
Date of signature:  2016, 9.12

Signature by legal agent (if necessary):  
Date of signature:  

Witness signature (if necessary):  
Date of signature:  

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers:  
Date of signature:  2016, 9.12
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

☐ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: [Signature] Date of signature: 2016.10.20

Signature by legal agent (if necessary): [Signature] Date of signature:

Witness signature (if necessary): [Signature] Date of signature:

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: [Signature] Date of signature: 2016.10.20
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy (NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer’s signature: __________________________ Date of signature: 2016, 12, 19

Signature by legal agent (if necessary): ______________ Date of signature: ______________

Witness signature (if necessary): ______________ Date of signature: ______________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: __________________________ Date of signature: 2016, 12, 19
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: [Signature] Date of signature: 2016.12.14

Signature by legal agent (if necessary): [Signature] Date of signature: 

Witness signature (if necessary): [Signature] Date of signature: 

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: [Signature] Date of signature: 2016.12.14
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02334663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer’s signature: _______________ Date of signature: _____________

Signature by legal agent (if necessary): _______________ Date of signature: ______________

Witness signature (if necessary): _______________ Date of signature: ______________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: _______________ Date of signature: _____________
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✔) in the box if you fully understand the content.

✔ I have read this agreement and fully understand the contents.

✔ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✔ I voluntarily participate in this study.

✔ I authorize the use and sharing of my health information as described in this consent form.

✔ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✔ I understand that my personal information is not used for any purpose other than research and is confidential.

✔ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✔ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: [Signature]
Date of signature: 2019.1.4

Signature by legal agent (if necessary): [Signature]
Date of signature: 

Witness signature (if necessary): [Signature]
Date of signature: 

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: [Signature]
Date of signature: 2019.1.4
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.
✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.
✓ I voluntarily participate in this study.
✓ I authorize the use and sharing of my health information as described in this consent form.
✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.
✓ I understand that my personal information is not used for any purpose other than research and is confidential.
✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.
✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: __________________________ Date of signature: 2019. 1. 5

Signature by legal agent (if necessary): __________ Date of signature: __________

Witness signature (if necessary): ________________ Date of signature: ________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: __________________________ Date of signature: 2019. 1. 5
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (√) in the box if you fully understand the content.

☐ I have read this agreement and fully understand the contents.

☐ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

☐ I voluntarily participate in this study.

☐ I authorize the use and sharing of my health information as described in this consent form.

☐ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

☐ I understand that my personal information is not used for any purpose other than research and is confidential.

☐ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

☐ I am free to request participation in the study and receive a copy of the consent form.

Signer’s signature: __________________________ Date of signature: 2017.1.5

Signature by legal agent (if necessary): __________ Date of signature: __________

Witness signature (if necessary): ________________ Date of signature: __________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: ______________________ Date of signature: 2017.1.5
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: [Signature] Date of signature: 2017. 1. 5
Signature by legal agent (if necessary): [Signature] Date of signature: [Signature] Date of signature:
Witness signature (if necessary): [Signature] Date of signature: [Signature]

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: [Signature] Date of signature: 2017. 1. 5
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834653 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer’s signature:  

Date of signature:  2017.3.13

Signature by legal agent (if necessary):  

Date of signature:  

Witness signature (if necessary):  

Date of signature:  

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers:  

Date of signature:  2017.3.13
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (√) in the box if you fully understand the content.

☐ I have read this agreement and fully understand the contents.

☐ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

☑ I voluntarily participate in this study.

☑ I authorize the use and sharing of my health information as described in this consent form.

☒ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

☑ I understand that my personal information is not used for any purpose other than research and is confidential.

☑ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

☐ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: _______________________________ Date of signature: 2017, 3, 16

Signature by legal agent (if necessary): _______________________________ Date of signature: ________________

Witness signature (if necessary): _______________________________ Date of signature: ________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: _______________________________ Date of signature: 2017, 3, 16
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
( NCT02834663 / CRFB002DKR03T )

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

☐ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

☐ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: __________________________ Date of signature: 2017, 3, 30

Signature by legal agent (if necessary): __________ Date of signature: __________

Witness signature (if necessary): ______________ Date of signature: __________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: __________________________ Date of signature: 2017, 3, 30
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

☐ I am free to request participation in the study and receive a copy of the consent form.

Signer’s signature: ___________________________ Date of signature: 2019.5.4

Signature by legal agent (if necessary): _______________ Date of signature: __________________

Witness signature (if necessary): _____________________ Date of signature: __________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: ________________________ Date of signature: 2019.5.4
Informed Consent Signature Page

Research Title :
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02334653 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.
✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.
✓ I voluntarily participate in this study.
✓ I authorize the use and sharing of my health information as described in this consent form.
✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: [Signature] Date of signature: 2019.5.29
Signature by legal agent (if necessary): [Signature] Date of signature:
Witness signature (if necessary): [Signature] Date of signature:

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: [Signature] Date of signature: 2019.5.29
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (√) in the box if you fully understand the content.

√ I have read this agreement and fully understand the contents.
√ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.
√ I voluntarily participate in this study.
√ I authorize the use and sharing of my health information as described in this consent form.
√ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.
√ I understand that my personal information is not used for any purpose other than research and is confidential.

√ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

√ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: ___________________________ Date of signature: 2019.6.14

Signature by legal agent (if necessary): ___________________________ Date of signature: ___________________________

Witness signature (if necessary): ___________________________ Date of signature: ___________________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: ___________________________ Date of signature: 2019.6.14
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02334663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: ___________________________ Date of signature: 2017.8.17

Signature by legal agent (if necessary): ___________________________ Date of signature: ___________________________

Witness signature (if necessary): ___________________________ Date of signature: ___________________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: ___________________________ Date of signature: 2017.8.17
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: Date of signature: 2017.9.6
Signature by legal agent (if necessary): Date of signature: 
Witness signature (if necessary): Date of signature: 

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: Date of signature: 2017.9.6
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.
✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.
✓ I voluntarily participate in this study.
✓ I authorize the use and sharing of my health information as described in this consent form.
✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.
✓ I understand that my personal information is not used for any purpose other than research and is confidential.
✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: [Signature] Date of signature: 2017.9.27

Signature by legal agent (if necessary): [Signature] Date of signature: [Signature]

Witness signature (if necessary): [Signature] Date of signature: [Signature]

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: [Signature] Date of signature: 2017.9.27
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: Date of signature: 2017-12-12

Signature by legal agent (if necessary): Date of signature:

Witness signature (if necessary): Date of signature:

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: Date of signature: 2017, 12.12
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy (NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: ___________________________ Date of signature: __2018, 1, 17__

Signature by legal agent (if necessary): ____________ Date of signature: ________________

Witness signature (if necessary): ________________ Date of signature: ________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: ________________________ Date of signature: __2018, 1, 17__
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: __________________________ Date of signature: ________________

Signature by legal agent (if necessary): __________________________ Date of signature: ________________

Witness signature (if necessary): __________________________ Date of signature: ________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: __________________________ Date of signature: ________________
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

☐ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

☐ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: __________________________ Date of signature: ________________

Signature by legal agent (if necessary): __________________________ Date of signature: 2018.5.28

Witness signature (if necessary): __________________________ Date of signature: ________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: __________________________ Date of signature: 2018.5.28
Informed Consent Signature Page

Research Title:
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
(NCT02834663 / CRFB002DKR03T)

Please read the information below and indicate (✓) in the box if you fully understand the content.

✓ I have read this agreement and fully understand the contents.

✓ I heard detailed explanations from the responsible researcher or co-researcher and asked questions and heard appropriate answers.

✓ I voluntarily participate in this study.

✓ I authorize the use and sharing of my health information as described in this consent form.

✓ I can refuse or stop participating in the study at any time during the study period.

Also, I understand that if I discontinue participation in this study, there will be no disadvantages to me.

✓ I understand that my personal information is not used for any purpose other than research and is confidential.

✓ I may be able to access the personal information of participants to verify the reliability of the data and the procedure for conducting the research by the relevant personnel (monitoring personnel, inspectors, committees, and ministries related to government) within the scope of the related regulations. I know there is.

✓ I am free to request participation in the study and receive a copy of the consent form.

Signer's signature: ___________________________ Date of signature: 2018.8.20

Signature by legal agent (if necessary): ___________________________ Date of signature: _______________

Witness signature (if necessary): ___________________________ Date of signature: ________________

We have read and explained the informed consent to the subject, and then answered all the questions he/she has raised. Him/herself has also already understood and agreed to participate in the scientific research.

Signatures of researchers: ___________________________ Date of signature: 2018.8.20